Clinical Trial

CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum

Study acronym: CHOPXE
Recruiting
View on ClinicalTrials.gov →
Summary
This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum. Pseudoxanthoma elasticum (PXE) is a rare, incurable hereditary disease caused by genetic mutations. The condition is characterised by excessive tissue mineralisation, which can result in a range of dermatological, vascular, and ophthalmological complications. Among these complications is the potential for visual impairment. The management of this condition is focused on the treatment of its complications. Degeneration of the retina and the choroid (the layer responsible for ensuring its vascularisation) occurs in the eye, resulting in premature degeneration. We would like to study the premature alteration of these structures, which could subsequently be used as an objective marker of the evolution of pseudoxanthoma elasticum.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-27; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07006649
Lead Sponsor University Hospital, Angers
Conditions Pseudoxanthoma Elasticum, Tomography, Optical Coherence, Retinal Disease
Enrollment 60 participants
Start Date 2025-11-28
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-08